Current and future approaches for treatment of paraneoplastic neurological syndromes with well-characterized onconeural antibodies

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Introduction: Paraneoplastic neurological syndromes (PNSs) are severely disabling conditions that are associated with cancer. Well-characterized onconeural antibodies (Abs) are, by definition, virtually exclusively present in patients with cancer and include anti-Hu, Yo, CV2, Ri, Ma2, amphiphysin and antidelta/notchlike epidermal growth factor-related receptor (DNER; Tr). More recently, a second group of antineuronal Abs has been described that are found in both patients with and without cancer. Areas covered: This review is focused on putative Tcellmediated immunopathogenetic mechanisms and treatment of PNS associated with well-characterized onconeural Abs. As of December 2013, only uncontrolled open-label clinical trials, retrospective case series and case reports were detected in the literature. Six clinical studies in HuPNS reported the effect of immunotherapy on functional outcome. Expert opinion: When taken together, these six studies showed an improvement of one point or more on the modified Rankin scale (mRS) in 11% (7/61) of patients. In Yo-PNS, 8% (2/26) of patients improved on the mRS. PNS with other well-characterized onconeural Abs also responded poorly to immunotherapies. Potential new immunotherapies include natalizumab, fingolimod, alemtuzumab and a combination of rituximab with cyclophosphamide.
Original languageUndefined/Unknown
Pages (from-to)483-496
Number of pages14
JournalExpert Opinion on Orphan Drugs
Issue number5
Publication statusPublished - 2014

Cite this